Skip to main content

Advertisement

SpringerLink
Log in

Physiological Aspects of Aging

Implications for the Treatment of Cancer

  • Review Article
  • Physiological Aspects of Aging
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The aging of the population has focused attention on the special needs of elderly patients. The increasing number of elderly people in the world’s population has led to a parallel increase in the number of older cancer patients. Bias against older patients for screening and treatment of cancer exists, whereby effective therapies are withheld in the mistaken belief that these patients cannot tolerate them.

Physiological changes which occur with aging include decreased cardiovascular performance, decreased haematopoietic tissue, a respiratory system which has been affected by life-long exposure to infection and toxins, decreasing renalfunction and a compromised nervous system. These changes have implications for drug toxicity such as possible increased sensitivity to cardiotoxins and increased haematological toxicity from myelosuppressive therapy. With the physiological decline in renal function with age, drug dosages must be carefully evaluated to avoid chemotherapy toxicity and its sequelae. Older patients may have increased sensitivity to oral toxicity, in particular, mucositis. There are also issues regarding tolerance of the older patient to radiation therapy.

The haematopoietic growth factors and new antiemetics now available will allow chemotherapy to be administered with greater safety while maintaining quality of life.

Overall, the healthy elderly are appropriate candidates for standard and experimental antineoplastic therapy. Careful assessment of end-organ function needs to be performed before a decision regarding the proper treatment regimen can be made. Clinical trials have rarely included the elderly, making data scarce. More research is needed in this age group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Koruda MJ, Sheldon GF. Surgery in the aged. Adv Surg 1991; 24: 292–331

    Google Scholar 

  2. Barry P, Katz PR. On cancer screening in the elderly [editorial]. J Am Geriatr Soc 1989; 37: 913–4

    PubMed  CAS  Google Scholar 

  3. Black JS, Kapoor W. Health promotion and disease prevention in older people. Our current state of ignorance. J Am Geriatr Soc 1990; 38: 168–72

    PubMed  CAS  Google Scholar 

  4. Robie PW. Cancer screening in the elderly. J Am Geriatr Soc 1989; 37: 888–93

    PubMed  CAS  Google Scholar 

  5. Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 1989; 63: 976–81

    PubMed  CAS  Google Scholar 

  6. Kennedy BJ. Aging and cancer. In: Balducci L, Lyman GH, Ershler WB, editors. Geriatric oncology. Philadelphia: JB Lippincott, 1992: 1–7

    Google Scholar 

  7. Yancik R, Yates JW, editors. Cancer in the elderly. Approaches to diagnosis and treatment. New York: Springer-Verlag, 1989

  8. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580–4

    PubMed  CAS  Google Scholar 

  9. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255: 3385–90

    PubMed  CAS  Google Scholar 

  10. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990; 355: 1020–2

    Google Scholar 

  11. Dixon DO, Neilan B, Jones S, et al. Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305

    PubMed  CAS  Google Scholar 

  12. Goodwin JS, Samet JM, Key CR, et al. Stage at diagnosis of cancer varies with age of the patient. J Am Geriatr Soc 1986; 34: 20–6

    PubMed  CAS  Google Scholar 

  13. Breslow L. Early case finding, treatment, and mortality from cervix and breast cancer. Prev Med 1971; 1: 141–52

    Google Scholar 

  14. Holmes FF, Hearne E. Cancer stage-to-age relationship: implications for cancer screening in the elderly. J Am Geriatr Soc 1981; 29: 55–7

    PubMed  CAS  Google Scholar 

  15. Lichtman SM, Budman DR. Adjuvant therapy for node-negative breast cancer [letter]. N Engl J Med 1989; 321: 470

    Google Scholar 

  16. Lichtman SM, Buchholtz M, Marino J, et al. Use of cisplatin in elderly patients. Age Ageing 1992; 21: 202–4

    PubMed  CAS  Google Scholar 

  17. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. Clin Oncol 1984; 21: 1406–14

    Google Scholar 

  18. Hrushesky WJM, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984; 76: 579–84

    PubMed  CAS  Google Scholar 

  19. Zaheer W, Lichtman SM, DeMarco LC, et al. Taxol use in the elderly [abstract]. Proc Am Soc Clin Oncol 1994; 13: 1518

    Google Scholar 

  20. Bécouarn Y, Nguyen B, Brunet R, et al. Cancer chemotherapy in the elderly: a series of 51 patients aged >70 years. Cancer Chemother Pharmacol 1992; 29: 159–63

    Google Scholar 

  21. Begg CB, Elson PJ, Carbone PP. A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols. In: Yancik R, Yates JW, editors. Cancer in the elderly. An approach to early detection and treatment. New York: Springer-Verlag, 1989: 149–63

    Google Scholar 

  22. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986–92

    PubMed  CAS  Google Scholar 

  23. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmond Oncology Association experience. JAMA 1992; 268: 57–62

    PubMed  CAS  Google Scholar 

  24. Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center Study. J Clin Oncol 1994; 12: 2447–52

    PubMed  CAS  Google Scholar 

  25. Repetto L, Vercelli M, Simoni C, et al. Comorbidity among elderly patients with and without cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: 1625

    Google Scholar 

  26. Satariano WA, Ragland DA. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104–10

    PubMed  CAS  Google Scholar 

  27. Peterson BA, Pajak TF, Cooper MR, et al. Effect of age on therapeutic response and survival in advanced Hodgkin’s disease. Cancer Treat Rep 1982; 66: 889–98

    PubMed  CAS  Google Scholar 

  28. Grover SA, Cook EF, Adam J, et al. Delayed diagnosis of gynecologic tumors in elderly women: relation to national medical practice patterns. Am J Med 1989; 86: 151–7

    PubMed  CAS  Google Scholar 

  29. Perry MC, editor. The chemotherapy source book. 1st ed. Baltimore: Williams & Wilkins, 1992

    Google Scholar 

  30. Balducci L, Lyman GH, Ershler WB, editors. Geriatric oncology, 1st ed. Philadelphia: J.B. Lippincott Company, 1992

    Google Scholar 

  31. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990; 6: 257–67

    PubMed  CAS  Google Scholar 

  32. Kinzel T, Feleppa V. Minimising the side effects of cancer chemotherapy in senior patients. Drugs Aging 1992; 2: 137–45

    PubMed  CAS  Google Scholar 

  33. Vestal RE. Clinical pharmacology. In: Andres R, Bierman EL, Hazzard WR, editors. Principles of geriatric medicine. New York: McGraw-Hill, 1990: 424–42

    Google Scholar 

  34. Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989; 16: 66–75

    PubMed  CAS  Google Scholar 

  35. Gurwitz JH, Avorn J. The ambiguous relationship between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956–66

    PubMed  CAS  Google Scholar 

  36. Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093–9

    PubMed  CAS  Google Scholar 

  37. Schwartz JB. Clinical pharmacology. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. New York: McGraw-Hill, Inc., 1994: 259–77

    Google Scholar 

  38. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993; 20: 43–9

    PubMed  CAS  Google Scholar 

  39. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology (Huntingt) 1992; 6 Suppl.: 62–8

    CAS  Google Scholar 

  40. Turner N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Ann Rev Pharmacol Toxicol 1992; 32: 271–302

    Google Scholar 

  41. Shock NW, Watkin DM, Yiengst BS, et al. Age differences in water content of the body as related to basal oxygen consumption in males. J Gerontol 1963; 18: 1–8

    PubMed  CAS  Google Scholar 

  42. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1978; 19: 653–63

    Google Scholar 

  43. Adelman LS, Liebman J. Anatomy of body water and electrolytes. Am J Med 1959; 27: 256–77

    Google Scholar 

  44. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994; 33: 493–6

    PubMed  CAS  Google Scholar 

  45. Hartock RJ, Smith EB, Petty C. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. Am J Clin Pathol 1965; 43: 326–31

    Google Scholar 

  46. Hoagland HC. Hematologic complications of cancer chemotherapy. Semin Oncol 1982; 9: 95–102

    PubMed  CAS  Google Scholar 

  47. Lipschitz DA. Aging of the hematopoietic system. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. New York: McGraw-Hill, Inc., 1994: 733–9

    Google Scholar 

  48. Williams LH, Udupa KB, Lipshitz DA, et al. An evaluation of the effect of age on hematopoiesis in C57BL/6 mouse. Exp Hematol 1986; 14: 827–32

    PubMed  CAS  Google Scholar 

  49. Lipschitz DA, Udapa KB, Milton KY, et al. Effect of age on hematopoiesis in man. Blood 1984; 63: 502–9

    PubMed  CAS  Google Scholar 

  50. Garry PJ, Goodwin JS, Hunt WC. Iron status and anemia in the elderly: new findings and a review of previous studies. J Am Geriatr Soc 1983; 31: 389–99

    PubMed  CAS  Google Scholar 

  51. Lipschitz DA. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995; 22 Suppl. 1: 3–5

    PubMed  CAS  Google Scholar 

  52. Udapa KB, Lipschitz DA. Erythropoiesis in the aged mouse: II. Response to stimulation in vivo. J Lab Clin Med 1984; 103: 581–8

    Google Scholar 

  53. Lipschitz DA. Nutrition, aging and the immunohematopoietic system. Clin Geriatr Med 1987; 3: 319–28

    PubMed  CAS  Google Scholar 

  54. Folkow B, Svanborg A. Physiology of cardiovascular aging. Physiol Rev 1993; 73: 725–64

    PubMed  CAS  Google Scholar 

  55. Tockman MS. Aging of the respiratory system. In: Katlic MR, editor. Geriatric surgery. Baltimore: Urban & Schwartzberg, 1990: 75–84

    Google Scholar 

  56. Evers BM, Townsend CMJ, Thompson JC. Organ physiology of aging. Surg Clin North Am 1994; 74: 23–39

    PubMed  CAS  Google Scholar 

  57. Dhar S, Shastri SR, Lenora RAK. Aging and the respiratory system. Med Clin North Am 1976; 60: 1121–39

    PubMed  CAS  Google Scholar 

  58. Wahba WM. The influence of aging on lung function-clinical significance of changes from age twenty. Anesth Analg 1983; 62: 764–76

    PubMed  CAS  Google Scholar 

  59. Brenner BM, Meyer GW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652–9

    PubMed  CAS  Google Scholar 

  60. Tauchi H, Tsuboi K, Okutoni J. Age changes in the human kidney of the different races. Gerontology 1971; 17: 87–97

    CAS  Google Scholar 

  61. Smythe M, Hoffman J, Kizy K, et al. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm 1994; 51: 198–204

    PubMed  CAS  Google Scholar 

  62. Lindeman RD. Renal physiology and pathophysiology of aging. Contrib Nephrol 1993; 105: 1–12

    PubMed  CAS  Google Scholar 

  63. Mangioni C, Bolis G, Pecorelli S, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81: 1464–71

    PubMed  CAS  Google Scholar 

  64. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56

    PubMed  CAS  Google Scholar 

  65. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985; 12: 125–36

    PubMed  Google Scholar 

  66. Von Glabbeke M, Renard J, Pinedo HM, et al. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trials conduced by the EORTC Early Clinical Trials Cooperative Group (ECTG). Eur J Cancer Clin Oncol 1988; 24: 255–62

    PubMed  Google Scholar 

  67. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol 1992; 19: 521–8

    PubMed  CAS  Google Scholar 

  68. MacDonald DR. Neurotoxicity of chemotherapeutic agents. In: Perry MC, editor. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992: 666–79

    Google Scholar 

  69. Byrne A, Carney DN. Cancer in the elderly. Curr Probl Cancer 1993; 17: 145–220

    PubMed  CAS  Google Scholar 

  70. Lamy PP. Physiological changes due to age. Pharmacodynamic changes of drug action and its implications for therapy. Drugs Aging 1991; 1: 385–404

    PubMed  CAS  Google Scholar 

  71. Ship JA, Baum BJ. Old age in health and disease. Lessons from the oral cavity. Oral Surg Oral Med Oral Pathol 1993; 76: 40–4

    PubMed  CAS  Google Scholar 

  72. Atkinson JC, Fox PC. Salivary gland dysfunction. Clin Geriatr Med 1992; 8: 499–511

    PubMed  CAS  Google Scholar 

  73. Kobayashi K, Ratain MJ. Individual dosing of cancer chemotherapy. Semin Oncol 1993; 20: 30–42

    PubMed  CAS  Google Scholar 

  74. Balducci L, Parker M, Sexton W, et al. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 76–84

    PubMed  CAS  Google Scholar 

  75. Shank WA, Balducci L. Recombinant hematopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc 1992; 40: 151–4

    PubMed  Google Scholar 

  76. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 492–501

    PubMed  CAS  Google Scholar 

  77. Gastineau DA, Hoagland HC. Hematologic effects of chemotherapy. Semin Oncol 1992; 19: 543–50

    PubMed  CAS  Google Scholar 

  78. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991; 324: 843–5

    PubMed  CAS  Google Scholar 

  79. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139–53

    PubMed  CAS  Google Scholar 

  80. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19: 529–42

    PubMed  CAS  Google Scholar 

  81. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7

    Google Scholar 

  82. Erbel R, Engberding R, Daniel W, et al. Echocardiography in diagnosis of aortic dissection. Lancet 1989; 1: 457–61

    PubMed  CAS  Google Scholar 

  83. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9

    PubMed  CAS  Google Scholar 

  84. Sugarman SM, Perez-Soler R. Liposomes in the treatment of malignancy: a clinical perspective. Crit Rev Oncol Hematol 1992; 12: 231–42

    PubMed  CAS  Google Scholar 

  85. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827–34

    PubMed  CAS  Google Scholar 

  86. Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978; 91: 168–75

    Google Scholar 

  87. Saini J, Rich W, Lyss AP. Reversibility of severe left ventricular function due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987; 106: 814–6

    PubMed  CAS  Google Scholar 

  88. Valagussa P, Zambertti M, Biasi S, et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 1994; 5: 209–16

    PubMed  CAS  Google Scholar 

  89. Lichtman SM, Budman D, Bosworth J, et al. Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. Am J Clin Oncol 1991; 14: 217–21

    Google Scholar 

  90. Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995; 22 Suppl. 1: 11–3

    PubMed  CAS  Google Scholar 

  91. Herman EH, Ferrans VJ. Amelioration of chronic anthracycline cardiotoxcity by ICRF-187 and other compounds. Cancer Treat Rev 1987; 14: 225–9

    PubMed  CAS  Google Scholar 

  92. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745–52

    PubMed  CAS  Google Scholar 

  93. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117–27

    PubMed  CAS  Google Scholar 

  94. Wei JY. Cardiovascular comorbidity in the older cancer patient. Semin Oncol 1995; 22 Suppl. 1: 9–10

    PubMed  CAS  Google Scholar 

  95. Bertelli G, Amoroso D, Pronzato P, et al. Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors. Anticancer Res 1988; 8: 645–6

    PubMed  CAS  Google Scholar 

  96. Villani F, Galimberti M, Comazzi R, et al. Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). Eur J Cancer Clin Oncol 1989; 25: 13–8

    PubMed  CAS  Google Scholar 

  97. Wood W, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl J Med 1994; 330: 1253–9

    PubMed  CAS  Google Scholar 

  98. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993; 15: 117–30

    PubMed  Google Scholar 

  99. Poplack DG, Balis FM, Zimm S. The pharmacology of orally administered chemotherapy. A reappraisal. Cancer 1986; 58 (2 Suppl.): 473–80

    CAS  Google Scholar 

  100. Zimm S, Collins JM, Riccardi R. Variable bioavailability of oral mercaptopurine. N Engl J Med 1983; 308: 1005–9

    PubMed  CAS  Google Scholar 

  101. Popper H. Aging and the liver. Prog Liver Dis 1986; 8: 659–83

    PubMed  CAS  Google Scholar 

  102. Balducci L, Phillips DM, Davis KM, et al. Systemic treatment of cancer in the elderly. Arch Gerontol Geriatr 1988; 7: 119–50

    PubMed  CAS  Google Scholar 

  103. Blanchley JD, Hill JB. Renal and electrolyte disturbances associated with Cisplatin. Ann Intern Med 1981; 95: 628–32

    Google Scholar 

  104. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1988; 25: 1–9

    Google Scholar 

  105. Becouarn Y, Bui BN, Brunet R, et al. Cancer chemotherapy in the elderly: a series of 51 patients aged >70 years. Cancer Chemother Pharmacol 1992; 29: 159–63

    Google Scholar 

  106. Sella A, Logothetis J, Dexfus RH, et al. Cisplatin combination chemotherapy for elderly patients with urothelial tumours. Br J Urol 1991; 67: 603–7

    PubMed  CAS  Google Scholar 

  107. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121–5

    PubMed  CAS  Google Scholar 

  108. Lyss AP. Enzymes and random synthetics. In: Perry MC, editor. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992: 398–412

    Google Scholar 

  109. Foster BJ, Clagett-Carr K, Leyland-Jones B, et al. Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 1985; 12: 43–9

    PubMed  Google Scholar 

  110. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994; 12: 2066–70

    PubMed  CAS  Google Scholar 

  111. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432–8

    PubMed  CAS  Google Scholar 

  112. Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985; 45: 6502–6

    PubMed  CAS  Google Scholar 

  113. Stoller RG, Jacobs SA, Drake JC, et al. Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemother Rep 1975; 6: 19–24

    Google Scholar 

  114. Schilsky RL. Antimetabolites. In: Perry MC, editor. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992: 301–17

    Google Scholar 

  115. Schaefer SD, Poster JD, Close LG, et al. Ototoxicity of low and moderate dose cisplatin. Cancer 1985; 56: 1934–9

    PubMed  CAS  Google Scholar 

  116. Baker WJ, Royer Jr GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991; 9: 679–93

    PubMed  CAS  Google Scholar 

  117. Rubin EH, Andersen JW, Berg DT, et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992; 10: 948–53

    PubMed  CAS  Google Scholar 

  118. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903

    PubMed  CAS  Google Scholar 

  119. Lichtman SM. Oral complaints in older cancer patients [letter]. Eur J Cancer B Oral Oncol 1993; 29B: 83

    PubMed  CAS  Google Scholar 

  120. Sonis ST, Sonis AL, Lieberman A. Oral complications in patients receiving treatments for non-head and neck malignancies. J Am Dent Assoc 1978; 97: 468–72

    PubMed  CAS  Google Scholar 

  121. Sonis ST. Oral complications of cancer therapy. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott, 1989: 2144–52

    Google Scholar 

  122. Dreizen S, Bodey GP, Valdivieso M. Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg Oral Med Oral Pathol 1983; 55: 113–20

    PubMed  CAS  Google Scholar 

  123. Rosenberg SW. Oral complications of cancer chemotherapy — a review of 398 patients. J Oral Med 1986; 41: 93–7

    PubMed  CAS  Google Scholar 

  124. Dolan TA, Monopoli M, Kalurich MJ, et al. Geriatric grand rounds: oral diseases in older adults. J Am Geriatr Soc 1990; 38: 1239–50

    PubMed  CAS  Google Scholar 

  125. Sonis S, Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head and neck malignancies. Oral Surg Oral Med Oral Pathol 1988; 65: 19–22

    PubMed  CAS  Google Scholar 

  126. Balducci L, Mowrey K, Parker M. Pharmacology of antineoplastic agents in older patients. In: Balducci L, Lyman GH, Ershler WB, editors. Geriatric oncology. Philadelphia: Lippincott, 1992: 169–80

    Google Scholar 

  127. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–26

    PubMed  CAS  Google Scholar 

  128. McCarthy GM, Skillings JR. Orofacial complications of chemotherapy for breast cancer. Oral Surg Oral Med Oral Pathol 1992; 74: 172–8

    PubMed  CAS  Google Scholar 

  129. Karr RA, Kramer DC, Toth BB. Dental implants and chemotherapy complications. J Prosthet Dent 1992; 67: 683–7

    PubMed  CAS  Google Scholar 

  130. Carl W, Emrich LS. Management of oral mucositis during local radiation and systemic chemotherapy: a study of 98 patients. J Prosthet Dent 1991; 66: 361–9

    PubMed  CAS  Google Scholar 

  131. Lichtman SM, Ratain MJ, Van Echo DA, et al. Phase I trial of granulocyte-macrophage colony stimulating factor (GM-CSF) plus high dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B phase I study. J Natl Cancer Inst 1993; 85: 1319–26

    PubMed  CAS  Google Scholar 

  132. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–70

    PubMed  CAS  Google Scholar 

  133. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471–508

    Google Scholar 

  134. Chatta GS, Price TH, Allen RC, et al. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923–9

    PubMed  CAS  Google Scholar 

  135. Vose JM. Cytokine use in the older patient. Semin Oncol 1995; 22 Suppl. 1: 6–8

    PubMed  CAS  Google Scholar 

  136. Larson RA, Linker CA, Dodge RK, et al. Granulocyte-colony stimulating factor (filgrastim; G-CSF) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukemia receiving intensive remission induction chemotherapy: Cancer and Leukemia Group B study 9111 [abstract]. Proc Am Soc Clin Oncol 1994; 13: 995

    Google Scholar 

  137. Stone R, George S, Berg D, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671–7

    PubMed  CAS  Google Scholar 

  138. Rowe JM, Andersen J, Mazza JJ, et al. Phase III randomized placebo-controlled study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG) [abstract]. Blood 1993; 82 (Suppl. 1): 1299

    Google Scholar 

  139. Miller CB, Platanias LC, Mills SR, et al. Phase I–II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992; 84: 98–103

    PubMed  CAS  Google Scholar 

  140. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78: 1658–63

    PubMed  CAS  Google Scholar 

  141. Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer 1994; 2: 286–92

    PubMed  CAS  Google Scholar 

  142. Wilson SE. Aminoglycosides: assessing the potential for nephrotoxicity. Surg Gynecol Obstet 1990; 171 Suppl.: 24–30

    PubMed  Google Scholar 

  143. Mylotte JM, Ksiazek S, Bentley DW. Rational approach to the antibiotic treatment of pneumonia in the elderly. Drugs Aging 1994; 4: 21–33

    PubMed  CAS  Google Scholar 

  144. Fields KK, Elfenbein GJ. Bone marrow transplantation in the older patient. In: Balducci L, Lyman GH, Ershler WB, editors. Geriatric oncology. Philadelphia: J.B. Lippincott, 1992: 190–8

    Google Scholar 

  145. Stewart D, Bierman P, Anderson J, et al. High dose chemotherapy with autologous hematopoietic rescue in patients age 60 and over [abstract]. Proc Am Soc Clin Oncol 1994; 13: 1260

    Google Scholar 

  146. Vesole DH, Jagannath S, Tricot G, et al. High-dose intensive therapy with autologous transplantation in multiple myeloma patients over age 60 [abstract]. Proc Am Soc Clin Oncol 1994; 13: 1400

    Google Scholar 

  147. Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–7

    PubMed  CAS  Google Scholar 

  148. Tobias JS. Clinical practice of radiotherapy. Lancet 1992; 339: 159–63

    PubMed  CAS  Google Scholar 

  149. Steinfeld AD, Diamond JJ, Hanks GE, et al. Patient age as a factor in radiotherapy. Data from the patterns of care study. J Am Geriatr Soc 1989; 37: 335–8

    PubMed  CAS  Google Scholar 

  150. Scalliet P. Radiotherapy in the elderly. Eur J Cancer 1991; 27: 3–5

    PubMed  CAS  Google Scholar 

  151. Peschel RE, Wilson L, Haffty B, et al. The effect of advanced age on the efficacy of radiation therapy for early breast cancer, local prostate cancer and grade III–IV gliomas. Int J Radiat Oncol Biol Phys 1993; 26: 539–44

    PubMed  CAS  Google Scholar 

  152. NIH consensus conference. Treatment of early breast cancer. JAMA 1991; 265: 391–5

    Google Scholar 

  153. Wyckoff J, Greenberg H, Sanderson R, et al. Breast irradiation in the older woman: a toxicity study. J Am Geriatr Soc 1994; 42: 150–2

    PubMed  CAS  Google Scholar 

  154. Stenfield AD, Diamond JJ, Hanks GE, et al. Patient age as a factor in radiotherapy. Data from the patterns of care study. J Am Geriatr Soc 1989; 37: 335–8

    Google Scholar 

  155. Roman DD, Sperduto PW. Neuropsychological effects of cranial radiation: current knowledge and future directions. Int J Radiat Oncol Biol Phys 1995; 31: 983–98

    PubMed  CAS  Google Scholar 

  156. Portnoy RK. Pain management in the older cancer patient. Oncology (Huntingt) 1992; 6 (2 Suppl.): 86–98

    Google Scholar 

  157. Brescia FJ, Adler D, Gray G, et al. Hospitalized advanced cancer patients: a profile. J Pain Symptom Manage 1990; 5: 222–7

    Google Scholar 

  158. Wall III RT. Use of analgesics in the elderly. Clin Geriatr Med 1990; 6: 345–64

    PubMed  Google Scholar 

  159. Bellville JW. Influence of age on pain relief from analgesics: a study of postoperative patients. JAMA 1971; 217: 1835–41

    PubMed  CAS  Google Scholar 

  160. Foley KM, Inturrisi CE. Analgesic drug therapy in cancer pain: principles and practice. Med Clin North Am 1987; 71: 207–32

    PubMed  CAS  Google Scholar 

  161. Schlebel SE, Paulus H. Non-steroidal and analgesic therapy in the elderly. Clin Rheum Dis 1986; 12: 245–74

    Google Scholar 

  162. Johnson AG, Seideman P, Day RO. Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs): recognition, management and avoidance. Drug Saf 1993; 8: 99–127

    PubMed  CAS  Google Scholar 

  163. Johnson AG, Day RO. The problems and pitfalls of NSAID in the elderly (part II). Drugs Aging 1991; 1: 212–27

    PubMed  CAS  Google Scholar 

  164. Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1991; 13: 1–23

    PubMed  CAS  Google Scholar 

  165. Bodd E, Jacobsen D, Lund E, et al. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 1990; 9: 317–21

    PubMed  CAS  Google Scholar 

  166. Osborne R, Joel S, Grebenik K, et al. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993; 54: 158–67

    PubMed  CAS  Google Scholar 

  167. Milne RW, Nation RL, Somogyi AA, et al. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol 1992; 34: 53–9

    PubMed  CAS  Google Scholar 

  168. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180–5

    PubMed  CAS  Google Scholar 

  169. Beghe C, Balducci L. Geriatric oncology: perspectives from decision analysis: a review. Arch Gerontol Geriatr 1990; 10: 141–62

    Google Scholar 

  170. Balducci L, Beghe C, Parker M, et al. Prognostic evaluation in geriatric oncology: problems and perspectives. Arch Gerontol Geriatr 1991; 13: 31–41

    PubMed  CAS  Google Scholar 

  171. Monfardini S, Chabner B. Joint NCI-EORTC consensus meeting on neoplasia in the elderly. Eur J Cancer 1991; 27: 653–4

    PubMed  CAS  Google Scholar 

  172. Monfardini S, Aapro M, Ferrucci L, et al. Commission of the European Communities ‘Europe Against Cancer’ programme European School of Oncology advisory report cancer treatment in the elderly. Eur J Cancer 1993; 29A: 2325–30

    PubMed  CAS  Google Scholar 

  173. Tchekmedyian NS, Cella DF, Mooradian AD. Care of the older cancer patient: clinical and quality of life issues. Oncology (Huntingt) 1992; 6 Suppl. 2: 1–160

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Don Monti Division of Medical Oncology, Department of Medicine, North Shore University Hospital —Cornell University Medical College, Manhasset, New York, USA

    Stuart M. Lichtman

Authors
  1. Stuart M. Lichtman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lichtman, S.M. Physiological Aspects of Aging. Drugs & Aging 7, 212–225 (1995). https://doi.org/10.2165/00002512-199507030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199507030-00006

Keywords

Search

Navigation